Bone Metabolism Therapeutics Market To 2018 - Hyperparathyroidism Sector To Decline In The Absence Of New Product Launches And Increased Generic Erosion For Zemplar, Hectorol And Sensipar

NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

http://www.reportlinker.com/p0887610/Bone-Metabolism-Therapeutics-Market-to-2018---Hyperparathyroidism-Sector-to-Decline-in-the-Absence-of-New-Product-Launches-and-Increased-Generic-Erosion-for-Zemplar-Hectorol-and-Sensipar.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

 

Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

 

Summary

 

GBI Research, the leading business intelligence provider, has released its latest research, "Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar", which provides insights into bone metabolic disease therapeutics until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major bone metabolic diseases, including osteoporosis, Paget's disease of bone, hyperparathyroidism and bone metastases. The report also provides the share of generics in global bone metabolic diseases as well as in each indication market. It also provides the treatment algorithm flow for each of the four indications. The report examines the global bone metabolic diseases treatment usage patterns. In addition, the geographical distribution of bone metabolic diseases and markets across the US, the top five countries of Europe, and in Japan, are provided in the report. The report also includes insights into the bone metabolic diseases R&D product pipeline and explores the competitive landscape, including major players in the bone metabolism therapeutics market. Finally, the report also includes analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the bone metabolism therapeutics market.

 

1 2 3 4 5 6 7 8 9 ... Next › Last »